Yvan Dierckxsens

Yvan Dierckxsens

Auto-generated profile, based on publicly available information

Yvan Dierckxsens

Tilman S.A., ZI Sud, Baillonville, Belgium

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
YHYves Henrotin
Yves Henrotin
MMM. Malaise
M. Malaise
RWR. Wittoek
R. Wittoek
KVK. de Vlam
K. de Vlam
JBJ.-P. Brasseur
J.-P. Brasseur
YDY. Dierckxsens
Y. Dierckxsens
Comparison of two doses of bio-optimized Curcuma longa extract (BCL) in the management of symptomatic knee osteoarthritis (OA). A prospective, randomized, 3-month, double-blind, multicenter, three-group, placebo-controlled trial assessing Patient Global Assessment of Disease Activity (PGADA) and serum sColl2-1, a biomarker of cartilage degradation, as co-primary endpoints. Pain on visual analog scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS), and paracetamol/non-steroidal anti-inflammatory drug (NSAID) consumption were used as secondary endpoints. One hundred fifty patients with knee OA were followed for 90 days. Low and high doses of BCL showed a greater decrease of PGADA than placebo. Analysis of sColl2-1 showed in the placebo and BCL low-dose groups, but not in the BCL high-dose group, a transient but non-significant increase of sColl2-1 between T0 and T1. Thereafter, in all groups, sColl2-1 decreased between T1 and T3 (all p < 0.01), but no difference between the groups was found. Pain reduction at day 90 in the low- and high-dose BCL groups (− 29.5 mm and − 36.5 mm) was higher than that in the placebo (− 8 mm; p = 0.018). The global KOOS significantly decreased overtime, but changes were comparable across treatment arms. The ratio of patients with adverse events (AE) related to the product was similar in the placebo and treatment groups, but the number of AE linked to the product was higher in the high-dose BCL group compared to the placebo (p = 0.012). BCL appeared safe and well-tolerated with no evidence of severe adverse effects. Efficacy analysis suggested positive trends for measurements of PGADA and serum levels of an OA biomarker and showed a rapid and significant decrease of pain in knee OA (Trial registration: NCT02909621, 21 September 2016 - retrospectively registered).

17 May 2014 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YHYves Henrotin
Yves Henrotin
MGMyriam Gharbi
Myriam Gharbi
YDYvan Dierckxsens
Yvan Dierckxsens
FPFabian Priem
Fabian Priem
MMMarc Marty
Marc Marty
CCCaroline Castermans
Caroline Castermans
The management of osteoarthritis (OA) remains a challenge. There is a need not only for safe and efficient treatments but also for accurate and reliable biomarkers that would help diagnosis and monitoring both disease activity and treatment efficacy. Curcumin is basically a spice that is known for its anti-inflammatory properties. In vitro studies suggest that curcumin could be beneficial for cartilage in OA. The aim of this exploratory, non-controlled clinical trial was to evaluate the effects of bio-optimized curcumin in knee OA patients on the serum levels of specific biomarkers of OA and on the evaluation of pain.

1 December 2017 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
CMChristian Tshongo Muhindo
Christian Tshongo Muhindo
SASylvie A. Ahn
Sylvie A. Ahn
MRMichel F. Rousseau
Michel F. Rousseau
YDYvan Dierckxsens
Yvan Dierckxsens
MHMichel P. Hermans
Michel P. Hermans

18 April 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
UWUrsula Wade
Ursula Wade
DPDomingo Pascual-Figal
Domingo Pascual-Figal
FRFazle Rabbani
Fazle Rabbani
MEMarie ERNST
Marie ERNST
AAAdelin Albert
Adelin Albert
AKAmjad Khan
Amjad Khan
Irritable bowel syndrome (IBS) is a prevalent chronic functional gastrointestinal disorder, characterised by recurrent abdominal discomfort and altered bowel movements. IBS cause a significantly negative impact on quality of life (QoL). Growing pharmacological evidence suggests that berberine (BBR) and curcumin (CUR) may mitigate IBS symptoms through multiple complementary synergistic mechanisms, resulting in the attenuation of intestinal inflammation and regulation of bowel motility and gut functions. In the present observational study conducted under real-life routine clinical practice settings, 146 patients diagnosed with IBS were enrolled by general practitioner clinics and pharmacies in Belgium. For the first time, this study assessed the potential synergistic pharmacological effect of a combined oral BBR/CUR supplement (Enterofytol® PLUS, containing 200 mg BBR and 49 mg CUR) (two tablets daily for 2 months), serving as complementary therapy in the management of IBS. Following the 2-month supplementation, significant improvements were observed in the patients’ IBS severity index (IBSSI) (47.5%) and all the primary IBS symptoms, such as abdominal discomfort (47.2%), distension (48.0%), intestinal transit (46.8%), and QoL (48.1%) (all p < 0.0001). The improvement in the patients’ IBSSI was independent of age, sex, and IBS sub-types. The patients’ weekly maximum stool passage frequency decreased significantly (p < 0.0001), and the stool status normalized (p < 0.0001). The patients’ need for concomitant conventional IBS treatment decreased notably: antispasmodics by 64.0% and antidiarrhoeals by 64.6%. Minor adverse effects were reported by a small proportion (7.1%) of patients, mostly gastrointestinal. The majority (93.1%) experienced symptom improvement or resolution, with a high satisfaction rate (82.6%) and willingness to continue the supplementation (79.0%). These findings support the potential synergistic pharmacological role of BBR and CUR in IBS, and their co-supplementation may alleviate IBS symptoms and improve QoL.